Information Provided By:
Fly News Breaks for October 1, 2015
SO, BBY, WMT, VRSK, RTN, RAI, MCD, LLY, EXR, DIS
Oct 1, 2015 | 10:37 EDT
BofA/Merrill named its Top 10 US Ideas for Q4 2015. Strategist Derek Harris chose the companies based on the most significant market and business related catalysts for the quarter. The list is made up of Buy rated stocks Disney (DIS), Extra Space Storage (EXR), Eli Lilly (LLY), McDonald's (MCD), Reynolds American (RAI), Raytheon (RTN), Verisk Analytics (VRSK), and Wal-Mart (WMT), and Underperform rated Best Buy (BBY) and Southern Company (SO).
News For DIS;EXR;LLY;MCD;RAI;RTN;VRSK;WMT;BBY;SO From the Last 2 Days
DIS
Mar 27, 2024 | 11:36 EDT
NetEase (NTES) unveiled a new team-based shooter "Marvel Rivals," a multiplayer game based on Marvel Comics' (DIS) superhero characters. The game is being developed for PC, with an alpha test for the game set to launch in May 2024. Reference Link
DIS
Mar 27, 2024 | 08:09 EDT
The Trian Group, which beneficially owns over $3.5 billion of common stock in The Walt Disney Company, announced that Egan-Jones is the second independent proxy advisory firm, along with Institutional Shareholder Services, to recommend that shareholders vote for change in the composition of the Disney board. Specifically, Egan-Jones recommends that Disney shareholders vote "FOR" both of Trian's nominees, Nelson Peltz and Jay Rasulo, and "WITHHOLD" on Maria Elena Lagomasino and Michael B.G. Froman in connection with Disney's annual meeting on April 3, 2024. Last week, ISS recommended that shareholders vote "FOR" Mr. Peltz and "WITHHOLD" on Ms. Lagomasino. Egan-Jones concluded: "We see very little downside and a lot of upsides in putting the Trian Nominees on the Board." Among the reasons Egan-Jones cited for the need for change at Disney were: "The apparent lack of a ... long-term succession plan." "A Board that appears cutoff and unwilling to engage with investors and the broader market." "A business model, we believe to be built for the last decade, but not forward looking and flexible enough to ensure success in the next." "A desire to protect the status quo for as long as possible and at all costs." "Mediocre financial performance and the resultant lower valuation." Similarly, ISS concluded that "incremental change is needed at the company due to multi-year underperformance the company's peers and chosen benchmark, operational challenges, and most critically, a repeated failure on the part of the board to oversee the cultivation of a successor..." In supporting the election of Mr. Peltz and the withholding of support for Ms. Lagomasino, ISS wrote that: Nelson Peltz is "well positioned to provide the catalyst that this board apparently needs to improve its effectiveness."
MCD
Mar 27, 2024 | 06:19 EDT
Citi analyst Jon Tower raised the firm's price target on Krispy Kreme (DNUT) to $19 from $14 and keeps a Neutral rating on the shares. The company's "long-awaited" McDonald's (MCD) partnership came in better than expected, with Krispy Kreme set to see its products sold at most U.S. locations by 2027 versus earlier discussions of a couple thousand stores, the analyst tells investors in a research note. The firm estimates this partnership alone could add $400M in revenue and $85M in EBITDA after full rollout. While execution risk remains, the news is "clearly a positive" for Krispy Kreme and investors, providing greater sales visibility for a brand that's been struggling with GLP-1 headlines and softer spend from lower-income consumers, says Citi.
MCD
Mar 26, 2024 | 16:25 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DIS
Mar 26, 2024 | 12:26 EDT
"Game On" is The Fly's weekly recap of the stories powering up or beating down video game stocks. NEW RELEASES: While... To see the rest of the story go to thefly.com. See Story Here
MCD
Mar 26, 2024 | 12:08 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
MCD
Mar 26, 2024 | 08:57 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly.  HIGHER - Krispy... To see the rest of the story go to thefly.com. See Story Here
LLY
Mar 26, 2024 | 07:08 EDT
JPMorgan estimates Amgen (AMGN) without its obesity pipeline is worth $240-$250 per share and that the market is assigning $30-$40 per share of value to Maritide. While the competitive bar for Maritide is high and moving higher based on Novo Nordisk's (NVO) recent pipeline updates, the obesity market is also "unprecedented in terms of size," the analyst tells investors in a research note. The firm estimates peak sales for Maritide of $6B, equating to mid-single-digit share within the incretin space. JPMorgan believes this supports a value roughly in-line with what is reflected in Amgen's current share price. It sees a positive risk/reward scenario given the recent pullback but maintains a Neutral rating on the name with a $290 price target. The firm says Amgen is viewed as the best positioned name beyond Eli Lilly (LLY) and Novo to have a role in the obesity space.